EDGAR Online

PROGENICS PHARMACEUTICALS INC

FORM 8-K
(Current report filing)

Filed 12/10/10 for the Period Ending 12/10/10

Address	777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591
Telephone	9147892800
CIK	0000835887
Symbol	PGNX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2010, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **December 10, 2010**

Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**000-23143**	**13-3379479**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York	**10591**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code **(914) 789-2800**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) has exercised its option under its Termination and Transition Agreement with Wyeth Pharmaceuticals, a division of Wyeth LLC (a Pfizer Inc. subsidiary), to have Wyeth continue to commercialize RELISTOR ® methylnaltrexone bromide in the United States through March 31, 2011. As previously announced, Wyeth is continuing to market and sell RELISTOR ex-U.S. through the same date, subject to early transition options available to Progenics.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ROBERT A. MCKINNEY

Robert A. McKinney

Chief Financial Officer, Senior Vice President, Finance & Operations and Treasurer

Date: December 10, 2010